ASP Launches 24-Minute EXPRESS Cycle for the STERRAD(R) 100NX(TM) SystemIRVINE, California - - New Cycle is One of the Fastest on the Market and is Validated to Sterilize da Vinci(R) 3D Endoscopes More Than 35 Million People Have Alzheimer’s and Dementia Worldwide, According To New ReportNEW YORK - More than 35 million people worldwide will have dementia in 2010, according to the 2009 World Alzheimer’s Report from Alzheimer’s Disease International (ADI). The new report was released on September 21st, which is World Alzheimer’s Day. Zeltiq(TM) Aesthetics Announces European CE Mark Approval for Non-Invasive Fat Layer Reduction Using Cryolipolysis(TM)NICE, France - - Impressive Clinical Results Presented at Major Scientific Meeting of Dermatologists and Plastic Surgeons from Five Continents Phase 3 Trial Shows Denosumab Delayed Skeletal Related Events in Advanced Cancer Patients With Bone MetastasesTHOUSAND OAKS, California - Amgen (Nasdaq: AMGN) today announced detailed results from a Phase 3 trial evaluating denosumab administered subcutaneously versus Zometa(R) (zoledronic acid) administered as an intravenous infusion in the treatment of bone metastases in 1,776 advanced cancer patients with solid tumors (not including breast and prostate cancer) or multiple myeloma. These results were presented today at the 2009 ECCO 15 - ESMO 34 European Multidisciplinary Congress in Berlin, Germany (Abstract Number: 20LBA). Simbionix USA Corporation’s Innovative Development Division Releases Two New Breakthrough TechnologiesCLEVELAND, Ohio - Simbionix USA Corporation, the world’s leading developer of medical simulation systems, just released two new products: a new Laparoscopic Essential Tasks Module for its LAP Mentor(TM) and a breakthrough technology for patient-specific simulation based on actual patient data - the PROcedure Rehearsal Studio(TM). Health Robotics Continues Global Expansion Into Oceania With Device Technologies Australia’s Strategic PartnershipBOZEN, Italy - Health Robotics today announced that it has signed an exclusive five-year strategic partnership with Device Technologies Australia Pty Ltd. for its revolutionary CytoCare(TM) Robot. This strategic agreement enables Device Technologies Australia to achieve its goal of safely, accurately and cost-effectively automating the preparation of Oncology I.V. Admixtures to complement its other market-leading Oncology and Surgery Robotic solutions. Leading Cardiovascular Surgeons Gather from Around the World to Share Ross Procedure Survival Data, Techniques at 2nd Annual SummitATLANTA - - Growing Outcomes Evidence Spurs Renewed Interest in Unique Heart Valve Procedure Abbott’s XIENCE V(R) Continues to Outperform TAXUS With Sustained Clinical Advantages and Impressive Long-Term Safety Results in SPIRIT III TrialSAN FRANCISCO - - Market-Leading XIENCE V Demonstrates Single-Digit Rate of Major Adverse Cardiac Events (MACE) at Three Years and a 43 Percent Reduction vs. TAXUS Drink-Drive Cambridgeshire Vet Warned as to Future ConductLONDON - Following a two-year postponed judgment, the Disciplinary Committee (DC) of the Royal College of Veterinary Surgeons last week [17 September 2009] warned a Cambridgeshire veterinary surgeon as to his future conduct, after he had been convicted in 2006 for causing death by careless driving whilst under the influence of alcohol. Occlutech and IZASA Obtains Favourable Ruling in Proceeding Initiated by AGA Medical in SpainZURICH - Occlutech AG, the leading European developer of products for septal closure, today announced that, together with its partner in Spain IZASA SA, it defeated a request for an injunction against sales and marketing activities in Spain, launched at the Commercial Court I of Barcelona, Spain by its U.S. competitor AGA Medical. Value of Text Verification Tool (TVT) Strongly Confirmed at RAPS in PhiladelphiaFRANKFURT - Trying economic times mean tight budgets. More projects, fewer people, rigid quality standards and competitve pressures are making the computer-driven proofreading tool made by Schlafender Hase more valuable than ever. Six Month Clinical Outcomes of Sahajanand Medical Technologies Supralimus - Sirolimus Eluting Stent presented at EuroPCR 09BARCELONA, Spain, May 20, 2009 - Six months Clinical outcome of Sahajanand Medical Technologies Supralimus-Sirolimus Eluting stent with Bioabsorbable Polymer was presented at EuroPCR 2009. This analysis was performed as a part of the prospective of E-Series Multicenter Registry. The dataset demonstrates excellent results in high risk patients with complex coronary lesions, including high procedural success rate (> 97%), and sustained safety. NeuroFocus Names Dr. Steven Miller to Head Global Neurological Laboratory OperationsBERKELEY, California - NeuroFocus, the world’s leading neuromarketing company, announced that it has named Dr. Steven L. Miller to lead its neurological testing laboratory facilities. Headquartered in Berkeley, the company operates its main lab there, with additional lab facilities and offices in Cincinnati, Dallas, Israel, Las Vegas, London, Los Angeles, New York, and Asia. Welsh Health Minister’s Ban on Advertising in Hospitals Will Cost the NHS GBP1 MillionLONDON - Health Minister Edwina Hart’s directive to ban all legal service advertising in hospitals could cost the Welsh NHS trusts GBP1 million in compensation through breached contracts. New Appointments at London Genetics to Drive Strategy ForwardLONDON - London Genetics Limited, which expedites pharmacogenetic partnerships between the biopharmaceutical industry and London-based centres of excellence in genetics research, announces today several prestigious appointments to its Board and management team. The new appointments, which include Dr Barrie Ward as Chairman, will drive the next phase of the company’s growth as the importance of pharmacogenetics in drug development increases. They bring important commercial, clinical and academic expertise. Amnis urges pre-squeeze acceleration in Community Services developmentThe specialist healthcare quality, innovation and productivity improvement enabler, Amnis, has outlined plans to transform the quality and productivity of Community Services. Malaria Control Method Could Prevent 6 Million New Infant CasesBARCELONA, Spain - - The Lancet Publishes New Findings Showing 30% Reduction in Babies Under 12 Months Using a WHO-Recommended Approach, but few African Countries Have Adopted it Power Plate International Ltd Certified as Medical Device ManufacturerLONDON - Power Plate International Limited, the leader in Acceleration Training(TM) exercise equipment, today received certification as a Medical Device Manufacturer within the European Economic Area (EEA). This was granted to Power Plate International Limited by the British Standards Institute (BSI), a world leader in the field of Medical Device regulation. Celebrities Give it Some Welly for Action Medical ResearchLONDON - - With Photo Nick Hewer and Margaret Mountford from The Apprentice, along with Davina McCall are all wearing their wellington boots this Friday to support the UK’s leading research charity Action Medical Research. Novasep Gains SafeBridge(R) “Potent Compound Safety Certification” for its Le Mans FacilityPOMPEY, France - Novasep is pleased to announce that its site in Le Mans - France, specialized in the development and manufacturing of Highly Potent Active Pharmaceutical Ingredients (HPAIs), has received the “Potent Compound Safety Certification” from SafeBridge(R) Consultants, Inc. Contraceptive Pill Named the Greatest Pharmacy Invention of the Last 150 Years in Chemist+Druggist CompetitionTONBRIDGE, England - The Contraceptive Pill has been crowned the greatest pharmacy innovation of the past 150 years, by leading figures in the drugs industry. AAF(R) Announces MEGAcel(TM) I Filter with Helior(TM) MediaLOUISVILLE, Kentucky - - MEGAcel I provides the highest efficiency at the lowest resistance in the industry. Call to Action to Prevent Deaths From Prostate Cancer in EuropeANTWERP, Belgium - - Leading Cancer Groups and Archbishop Desmond Tutu Unite in Call to Action in the Fight Against Prostate Cancer Investment in Health Benefits is on the UpANDOVER, England - Despite the economic downturn, companies are more than doubling their spend on healthcare benefits, according to new research from Simplyhealth’s Bothered Britain Report 2009, which is released this month. The report investigates how attitudes, policy and behaviour have changed in the past year towards health-related issues, as well as looking at newer trends that are impacting on workplace health. Sanaria Inc. Receives Multi-Year U.S. NIH Phase II Small Business Innovation Research Grant to Enhance Efficiency and Scale-up of its Malaria Vaccine Manufacturing ProcessROCKVILLE, Maryland - Sanaria Inc. has received additional support from the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health in the form of a Phase II Small Business Innovation Research (SBIR) Grant. The award for two years is US$1.99 million. Subject to satisfactory progress by Sanaria, continued funding for a third year will bring the total to nearly US$3 million. This new funding will facilitate efforts to increase the efficiency and scale-up of manufacturing and release processes to the levels required for Phase 3 clinical testing, licensure, and commercial launch of Sanaria(TM) PfSPZ, Sanaria’s attenuated whole parasite malaria sporozoite vaccine. Merck Serono Growth Hormone Injection Device easypod(R) Approved in JapanGENEVA - Merck Serono, a division of Merck KGaA Darmstadt, Germany, today announced that the Japanese health authorities, the Pharmaceutical and Medical Devices Agency (PMDA), have granted a marketing authorization for easypod(R) in Japan. Easypod(R) was developed for exclusive use with cartridges of Saizen(R) (somatropin), Merck Serono’s human recombinant growth hormone for the treatment of growth hormone deficiency. New Testing Option Extends Scope of Food Safety ScreeningHILLEROD, Denmark - FOSS has extended the availability of software functionality that helps to spot adulterated raw milk. Amgen Scholars Europe Programme Convenes Undergraduates From 15 Countries for Innovative Science ResearchCAMBRIDGE, England - - Symposium Offers Unique Opportunity to Meet Peers and Leading Scientists; Discuss Hands-On Summer Research Projects /C O R R E C T I O N — Merck Serono S A/GENEVA - In the news release, “Merck Serono Growth Hormone Injection Device easypod(R) Approved in Japan” issued on 16 Sep 2009 07:00 GMT, by Merck Serono S A SWX:SEO over PR Newswire, we are advised by a representative of the company that the last sentence of the fourth paragraph has been changed from “In Japan, easypod(R) will be launched in September 2009″ to “In Japan, easypod(R) will be launched in the course of 2009″ as originally issued inadvertently. Complete, corrected release follows: New Collaborations and Breakthrough Advancements in RNA-Based Drug Development Programs Lead Santaris Pharma A/S to Establish US OperationsHOERSHOLM, Denmark and SAN DIEGO, California - - Denmark-Based Santaris Pharma A/S Appoints Leading RNA Industry Expert Art Levin Ph.D. as President of US Operations and Chief Development Officer Children’s Hospital in Colorado Rounds off List of 24 Cord Blood Transplant Centers Worldwide Enrolling for ExCell Trial Studying StemEx(R) for Leukemia and LymphomaDENVER, Colorado and JERUSALEM - Children’s Hospital of Colorado and the Gamida Cell-Teva Joint Venture announced today that Children’s Hospital is enrolling patients for the ExCell study. Children’s Hospital is the 24th in a series of cord blood transplant sites worldwide, five of which are children’s centers, participating in the study in the U.S., Spain, Italy, Hungary and Israel. The trial is researching the safety and efficacy of StemEx as a therapeutic treatment for patients with blood cancers like leukemia and lymphoma. SecureWorks, Inc. Streamlines the PCI AOC and FFIEC ITO Self-Assessment Questionnaire Processes with Predefined Assessment Programs and Affiliate Compliance Summary ReportsATLANTA and LONDON - SecureWorks(R), a leading, global provider of security services, is streamlining the Payment Card Industry (PCI) Attestation of Compliance (AOC) and FFIEC Information Technology Outsourcing (ITO) Self-Assessment Questionnaire processes with Predefined Assessment Programs. These programs are preconfigured with assessment questions based on the PCI and FFIEC guidelines. An organisation’s affiliates (vendors, partners, internal departments, and service providers) are then rated in accordance with their compliance with these regulations. New Nominee for WHO Regional Director for EuropeCOPENHAGEN - Zsuzsanna Jakab has been nominated as the new WHO Regional Director for Europe by the WHO European Region’s governing body in Copenhagen. Mrs Jakab, the first representative of Hungary to lead a WHO region, is currently Director of the European Centre for Disease Prevention and Control. She was one of five candidates for the post. Guided Delivery Systems, Inc. Successfully Treats First Patient with Mitral RegurgitationSANTA CLARA, California - Guided Delivery Systems, Inc. (”GDS”) announced the first successful percutaneous implantation of the GDS Accucinch(R) System for mitral valve repair. The procedure was performed by Prof. Dr. med. Joachim Schofer of Medizinisches Versorgungszentrum, Hamburg University Cardiovascular Center in Hamburg, Germany. The GDS Accucinch System significantly reduced the patient’s mitral regurgitation without requiring open heart surgery. Amgen to Present Pivotal Data From Four Phase 3 Studies at the ECCO 15 - ESMO 34 CongressTHOUSAND OAKS, California - - Key Denosumab and Vectibix(R) (Panitumumab) Data to be Presented |
